EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer

BACKGROUND: Cisplatin-based chemotherapy is recommended as the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, the benefits are limited due to the acquisition of drug resistance. The mechanisms of resistance remain unclear. Although there are some...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamura, Shunsuke, Yoshino, Hirofumi, Kuroshima, Kazuki, Tsuruda, Masafumi, Osako, Yoichi, Sakaguchi, Takashi, Yonemori, Masaya, Yamada, Yasutoshi, Tatarano, Shuichi, Nakagawa, Masayuki, Enokida, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798329/
https://www.ncbi.nlm.nih.gov/pubmed/33430801
http://dx.doi.org/10.1186/s12885-020-07717-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798329/
https://www.ncbi.nlm.nih.gov/pubmed/33430801
http://dx.doi.org/10.1186/s12885-020-07717-0

Ejemplares similares